Literature DB >> 16116665

Use of combinations of antipsychotics: McLean Hospital inpatients, 2002.

Franca Centorrino1, Kate V Fogarty, Gabriele Sani, Paola Salvatore, Stephanie L Cincotta, John Hennen, Francesca Guzzetta, Alessandra Talamo, Mark G Saadeh, Ross J Baldessarini.   

Abstract

BACKGROUND: The empirical use of combinations of antipsychotic agents appears to be increasing with little research support for the relative efficacy, safety or cost-effectiveness of this practice. Such treatment was evaluated in hospitalized psychiatric patients.
METHODS: Samples of consecutive inpatients treated with > or = 2 ('polytherapy') vs 1 antipsychotic ('monotherapy') were matched on age, sex, diagnosis and admission clinical ratings, and these groups were compared on total daily chlorpromazine-equivalent doses, days in hospital, and changes in clinical ratings between admission and discharge.
RESULTS: The study sample included 69 polytherapy and 115 well-matched monotherapy subjects. Despite matching for initial CGI and GAF ratings, polytherapy was associated with high PANSS subscale scores of positive symptoms among affective psychosis, and relatively greater PANSS subscale ratings of excitement-agitation among patients diagnosed with schizophrenia. Estimated clinical improvement during hospitalization was similar among poly- and monotherapy patients, but total daily CPZ-eq doses at discharge averaged twice-greater with polytherapy, and hospitalization lasted 1.5 times longer.
CONCLUSIONS: Antipsychotic polytherapy as well as the types of agents combined may reflect clinician responses to particular symptom patterns. The value of specific combinations of antipsychotic agents and their comparison with monotherapies requires specific, prospective, randomized and well-controlled trials that consider matching on clinical characteristics and truly comparable doses across regimens. (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116665     DOI: 10.1002/hup.719

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  11 in total

1.  Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia.

Authors:  Sa Jacob; Mi Mohamed Ibrahim; F Mohammed
Journal:  Ment Health Fam Med       Date:  2013-01

Review 2.  Antipsychotic combinations for schizophrenia.

Authors:  Javier Ortiz-Orendain; Santiago Castiello-de Obeso; Luis Enrique Colunga-Lozano; Yue Hu; Nicola Maayan; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-06-28

3.  Comparison of mania patients suitable for treatment trials versus clinical treatment.

Authors:  Alessandra Talamo; Ross J Baldessarini; Franca Centorrino
Journal:  Hum Psychopharmacol       Date:  2008-08       Impact factor: 1.672

Review 4.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

5.  Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.

Authors:  Julie A Kreyenbuhl; Marcia Valenstein; John F McCarthy; Dara Ganoczy; Frederic C Blow
Journal:  Psychiatr Serv       Date:  2007-04       Impact factor: 3.084

6.  Adding or switching antipsychotic medications in treatment-refractory schizophrenia.

Authors:  Julie Kreyenbuhl; Steven C Marcus; Joyce C West; Joshua Wilk; Mark Olfson
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084

7.  Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis.

Authors:  Aurelie Millier; Emmanuelle Sarlon; Jean-Michel Azorin; Laurent Boyer; Samuel Aballea; Pascal Auquier; Mondher Toumi
Journal:  BMC Psychiatry       Date:  2011-02-11       Impact factor: 3.630

8.  Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process.

Authors:  Giouliana Kadra; Robert Stewart; Hitesh Shetty; Richard G Jackson; Mark A Greenwood; Angus Roberts; Chin-Kuo Chang; James H MacCabe; Richard D Hayes
Journal:  BMC Psychiatry       Date:  2015-07-22       Impact factor: 3.630

9.  Antipsychotic polypharmacy prescribing and risk of hospital readmission.

Authors:  Giouliana Kadra; Robert Stewart; Hitesh Shetty; James H MacCabe; Chin-Kuo Chang; Jad Kesserwani; David Taylor; Richard D Hayes
Journal:  Psychopharmacology (Berl)       Date:  2017-10-28       Impact factor: 4.530

10.  Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.

Authors:  Giouliana Kadra; Robert Stewart; Hitesh Shetty; Johnny Downs; James H MacCabe; David Taylor; Richard D Hayes
Journal:  Schizophr Res       Date:  2016-04-16       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.